EXONDYS 51

EXONDYS 51

Challenge: Launch the first treatment for Duchenne muscular dystrophy, a progressive and fatal muscle wasting disease, in a tumultuous approval environment.

Action: Nimbly partnering with the commercial team, we created an entire suite of launch strategies - and corresponding communications materials - to compliantly address all possible FDA scenarios. Across digital and print, patient and HCP-facing channels, we carefully crafted the strategy, content and assets to effectively bring a much-needed medicine to the community.

|